Adefovir: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 22: | Line 22: | ||
'''| [[Adefovir clinical studies|Clinical Studies]]''' | '''| [[Adefovir clinical studies|Clinical Studies]]''' | ||
'''| [[Adefovir dosage and administration|Dosage and Administration]]''' | '''| [[Adefovir dosage and administration|Dosage and Administration]]''' | ||
'''| [[Adefovir how supplied|How Supplied]]''' | '''| [[Adefovir how supplied|How Supplied]]''' | ||
'''| [[Adefovir labels and packages|Labels and Packages]]''' | '''| [[Adefovir labels and packages|Labels and Packages]]''' | ||
Revision as of 00:49, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon® and Hepsera®, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is a failed treatment for HIV.
Category
Antiviral
US Brand Names
HEPSERA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages